Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis

  • Harvey G. Moore
  • Nancy N. Baxter
  • Jose G. Guillem


Colorectal cancer (CRC) is a disease with a major worldwide burden. It is the fourth most frequently diagnosed malignancy in men and third most common in women, with almost one million people developing CRC annually.1 In the world, CRC is the third most common cause of cancer death, responsible for 639,000 deaths annually.2 In the USA, CRC is the third most common cancer in men and women and the second most common cause of cancer death overall, accounting for 11% of cancers diagnosed.3 It was estimated that 147,000 cases were diagnosed in the USA in 2009 and that there were 50,000 deaths from the disease.3


Rectal Cancer Hormone Replacement Therapy Familial Adenomatous Polyposis Colorectal Adenoma Aberrant Crypt Focus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization Mortality Datebase. World Health Organization. (Accessed 9 Dec 2009, at
  3. 3.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRefGoogle Scholar
  4. 4.
    Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ. 2000;321:805–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Rabeneck L, Davila JA, El-Serag HB. Is there a true “shift” to the right colon in the incidence of colorectal cancer? Am J Gastroenterol. 2003;98:1400–9.PubMedGoogle Scholar
  6. 6.
    American Cancer Society Website Cancer Facts and ­Figures. Accessed 16 Dec 2009.
  7. 7.
    O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–72.PubMedGoogle Scholar
  8. 8.
    Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet. 1997;17:79–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheng X, Chen VW, Steele B, et al. Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group in the United States, 1992–1997. Cancer. 2001;92:2547–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975–1994. Cancer. 1999;85:1670–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Lagiou P, Adami HO. Burden of cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of cancer epidemiology. Oxford: Oxford University Press; 2002. p. 3–28.Google Scholar
  12. 12.
    Burkitt DP. Related disease–related cause? Lancet. 1969;2:1229–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Flood DM, Weiss NS, Cook LS, Emerson JC, Schwartz SM, Potter JD. Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes Control. 2000;11:403–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 2003;97:3133–275.PubMedCrossRefGoogle Scholar
  15. 15.
    Rabeneck L, El-Serag HB, Davila JA, Sandler RS. Outcomes of colorectal cancer in the United States: no change in survival (1986–1997). Am J Gastroenterol. 2003;98:471–7.PubMedGoogle Scholar
  16. 16.
    Anderson WF, Umar A, Brawley OW. Colorectal carcinoma in black and white race. Cancer Metastasis Rev. 2003;22:67–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Morris AM, Billingsley KG, Baxter NN, Baldwin LM. Racial disparities in rectal cancer treatment: a population-based analysis. Arch Surg. 2004;139:151–5. discussion 6.PubMedCrossRefGoogle Scholar
  18. 18.
    National Cancer Society Cancer Control and Population Sciences Estimated US Cancer Prevalence. Accessed 16 Dec 2009.
  19. 19.
    Nigro ND, Singh DV, Campbell RL, Sook M. Effect of dietary beef fat on intestinal tumor formation by azoxymethane in rats. J Natl Cancer Inst. 1975;54:439–42.PubMedGoogle Scholar
  20. 20.
    Reddy BS, Narisawa T, Vukusich D, Weisburger JH, Wynder EL. Effect of quality and quantity of dietary fat and dimethylhydrazine in colon carcinogenesis in rats. Proc Soc Exp Biol Med. 1976;151:237–9.PubMedGoogle Scholar
  21. 21.
    Hursting SD, Thornquist M, Henderson MM. Types of dietary fat and the incidence of cancer at five sites. Prev Med. 1990;19:242–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Willett WC. Dietary fat intake and cancer risk: a controversial and instructive story. Semin Cancer Biol. 1998;8:245–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Howe GR, Aronson KJ, Benito E, et al. The relationship between dietary fat intake and risk of colorectal cancer: evidence from the combined analysis of 13 case-control studies. Cancer Causes Control. 1997;8:215–28.PubMedCrossRefGoogle Scholar
  24. 24.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res. 1994;54:2390–7.PubMedGoogle Scholar
  25. 25.
    Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 1990;323:1664–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Flood A, Velie EM, Sinha R, et al. Meat, fat, and their subtypes as risk factors for colorectal cancer in a prospective cohort of women. Am J Epidemiol. 2003;158:59–68.PubMedCrossRefGoogle Scholar
  27. 27.
    Weijenberg MP, Luchtenborg M, de Goeij AF, et al. Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. Cancer Causes Control. 2007;18:865–79.PubMedCrossRefGoogle Scholar
  28. 28.
    Beresford SA, Johnson KC, Ritenbaugh C, et al. Low-fat dietary pattern and risk of colorectal cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:643–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Bingham SA, Pignatelli B, Pollock JR, et al. Does increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon ­cancer? Carcinogenesis. 1996;17:515–23.PubMedCrossRefGoogle Scholar
  30. 30.
    de Kok TM, van Maanen JM. Evaluation of fecal mutagenicity and colorectal cancer risk. Mutat Res. 2000;463:53–101.PubMedCrossRefGoogle Scholar
  31. 31.
    de Vogel J, van-Eck WB, Sesink AL, Jonker-Termont DS, Kleibeuker J, van der Meer R. Dietary heme injures surface epithelium resulting in hyperproliferation, inhibition of apoptosis and crypt hyperplasia in rat colon. Carcinogenesis. 2008;29:398–403.PubMedCrossRefGoogle Scholar
  32. 32.
    Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer. 2006;119:2657–64.PubMedCrossRefGoogle Scholar
  33. 33.
    Sandhu MS, White IR, McPherson K. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev. 2001;10:439–46.PubMedGoogle Scholar
  34. 34.
    Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer. 2002;98:241–56.PubMedCrossRefGoogle Scholar
  35. 35.
    Morita M, Le Marchand L, Kono S, et al. Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Epidemiol Biomarkers Prev. 2009;18:235–41.PubMedCrossRefGoogle Scholar
  36. 36.
    World. Cancer Research Fund/American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. In: 1997 Washington DC: American Institute for Cancer Research 1997.Google Scholar
  37. 37.
    Michels KB, Edward G, Joshipura KJ, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst. 2000;92:1740–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Voorrips LE, Goldbohm RA, van Poppel G, Sturmans F, ­Hermus RJ, van den Brandt PA. Vegetable and fruit consumption and risks of colon and rectal cancer in a prospective cohort study: The Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol. 2000;152:1081–92.PubMedCrossRefGoogle Scholar
  39. 39.
    McCullough ML, Robertson AS, Chao A, et al. A prospective study of whole grains, fruits, vegetables and colon cancer risk. Cancer Causes Control. 2003;14:959–70.PubMedCrossRefGoogle Scholar
  40. 40.
    Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst. 2007;99:1471–83.PubMedCrossRefGoogle Scholar
  41. 41.
    van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, et al. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2009;89:1441–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000;342:1149–55.PubMedCrossRefGoogle Scholar
  43. 43.
    Michels KB, Giovannucci E, Chan AT, Singhania R, Fuchs CS, Willett WC. Fruit and vegetable consumption and colorectal adenomas in the Nurses’ Health Study. Cancer Res. 2006;66:3942–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Millen AE, Subar AF, Graubard BI, et al. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am J Clin Nutr. 2007;86:1754–64.PubMedGoogle Scholar
  45. 45.
    Sengupta S, Tjandra JJ, Gibson PR. Dietary fiber and colorectal neoplasia. Dis Colon Rectum. 2001;44:1016–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999;340:169–76.PubMedCrossRefGoogle Scholar
  47. 47.
    Peters U, Sinha R, Chatterjee N, et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet. 2003;361:1491–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet. 2003;361:1496–501.PubMedCrossRefGoogle Scholar
  49. 49.
    Bingham SA, Norat T, Moskal A, et al. Is the association with fiber from foods in colorectal cancer confounded by folate intake? Cancer Epidemiol Biomarkers Prev. 2005;14:1552–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA. 2005;294:2849–57.PubMedCrossRefGoogle Scholar
  51. 51.
    Schatzkin A, Mouw T, Park Y, et al. Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr. 2007;85:1353–60.PubMedGoogle Scholar
  52. 52.
    Wakai K, Date C, Fukui M, et al. Dietary fiber and risk of colorectal cancer in the Japan collaborative cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:668–75.PubMedCrossRefGoogle Scholar
  53. 53.
    Asano T, McLeod RS. Dietary fibre for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2002:CD003430.Google Scholar
  54. 54.
    Sansbury LB, Wanke K, Albert PS, Kahle L, Schatzkin A, Lanza E. The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence. Am J Epidemiol. 2009;170:576–84.PubMedCrossRefGoogle Scholar
  55. 55.
    Larsson SC, Giovannucci E, Bergkvist L, Wolk A. Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60,000 women. Br J Cancer. 2005;92:1803–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med. 1999;340:101–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet. 2000;356:1300–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev. 2008:CD003548.Google Scholar
  59. 59.
    Bergsma-Kadijk JA, van’t Veer P, Kampman E, Burema J. Calcium does not protect against colorectal neoplasia. Epidemiology. 1996;7:590–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst. 2004;96:1015–22.PubMedCrossRefGoogle Scholar
  61. 61.
    Ishihara J, Inoue M, Iwasaki M, Sasazuki S, Tsugane S. Dietary calcium, vitamin D, and the risk of colorectal cancer. Am J Clin Nutr. 2008;88:1576–83.PubMedCrossRefGoogle Scholar
  62. 62.
    Larsson SC, Bergkvist L, Rutegard J, Giovannucci E, Wolk A. Calcium and dairy food intakes are inversely associated with colorectal cancer risk in the Cohort of Swedish Men. Am J Clin Nutr. 2006;83:667–73. quiz 728–9.PubMedGoogle Scholar
  63. 63.
    Park Y, Leitzmann MF, Subar AF, Hollenbeck A, Schatzkin A. Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study. Arch Intern Med. 2009;169:391–401.PubMedCrossRefGoogle Scholar
  64. 64.
    Park SY, Murphy SP, Wilkens LR, Nomura AM, Henderson BE, Kolonel LN. Calcium and vitamin D intake and risk of colorectal cancer: the Multiethnic Cohort Study. Am J Epidemiol. 2007;165:784–93.PubMedCrossRefGoogle Scholar
  65. 65.
    Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684–96.PubMedCrossRefGoogle Scholar
  66. 66.
    Forman MR, Levin B. Calcium plus vitamin D3 supplementation and colorectal cancer in women. N Engl J Med. 2006;354:752–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention – an overview of the science. Gastroenterology. 2004;126:1423–47.PubMedCrossRefGoogle Scholar
  68. 68.
    Garland CF, Garland FC, Gorham ED. Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. Ann NY Acad Sci. 1999;889:107–19.PubMedCrossRefGoogle Scholar
  69. 69.
    Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001;154:369–87.PubMedCrossRefGoogle Scholar
  70. 70.
    Gaschott T, Steinmeyer A, Steinhilber D, Stein J. ZK 156718, a low calcemic, antiproliferative, and prodifferentiating vitamin D analog. Biochem Biophys Res Commun. 2002;290:504–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Holt PR, Arber N, Halmos B, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev. 2002;11:113–9.PubMedGoogle Scholar
  72. 72.
    Woolcott CG, Wilkens LR, Nomura AM, et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2010;19:130–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E. Vitamin D and prevention of colorectal adenoma: a meta-­analysis. Cancer Epidemiol Biomarkers Prev. 2008;17:2958–69.PubMedCrossRefGoogle Scholar
  74. 74.
    Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther. 2009;30:113–25.PubMedCrossRefGoogle Scholar
  75. 75.
    Huncharek M, Muscat J, Kupelnick B. Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26,335 cases from 60 observational studies. Nutr Cancer. 2009;61:47–69.PubMedCrossRefGoogle Scholar
  76. 76.
    Kim YI. Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen. 2004;44:10–25.PubMedCrossRefGoogle Scholar
  77. 77.
    Hunter DJ. In: Environmental Mutagen Society Colon Cancer Conference; 2003 May 14–16, 2003; Miami Florida; 2003.Google Scholar
  78. 78.
    Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134:29–38.PubMedCrossRefGoogle Scholar
  79. 79.
    Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Ulrich CM, Potter JD. Folate and cancer – timing is everything. JAMA. 2007;297:2408–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Luebeck EG, Moolgavkar SH, Liu AY, Boynton A, Ulrich CM. Does folic acid supplementation prevent or promote colorectal cancer? Results from model-based predictions. Cancer Epidemiol Biomarkers Prev. 2008;17:1360–7.PubMedCrossRefGoogle Scholar
  82. 82.
    U.S. Food and Drug Adminstration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Final rule. 21 DFR Parts 136, 137, and 139. Fed. Regsit. 1996; 61:8781–807. In; 1996.Google Scholar
  83. 83.
    Mason JB, Dickstein A, Jacques PF, et al. A temporal ­association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007;16:1325–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Longnecker MP, Orza MJ, Adams ME, Vioque J, Chalmers TC. A meta-analysis of alcoholic beverage consumption in relation to risk of colorectal cancer. Cancer Causes Control. 1990;1:59–68.PubMedCrossRefGoogle Scholar
  85. 85.
    Moskal A, Norat T, Ferrari P, Riboli E. Alcohol intake and ­colorectal cancer risk: a dose-response meta-analysis of published cohort studies. Int J Cancer. 2007;120:664–71.PubMedCrossRefGoogle Scholar
  86. 86.
    Mizoue T, Inoue M, Wakai K, et al. Alcohol drinking and ­colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol. 2008;167:1397–406.PubMedCrossRefGoogle Scholar
  87. 87.
    Ferrari P, Jenab M, Norat T, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2007;121:2065–72.PubMedCrossRefGoogle Scholar
  88. 88.
    Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298:754–64.PubMedCrossRefGoogle Scholar
  89. 89.
    Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11:376–81.PubMedCrossRefGoogle Scholar
  90. 90.
    Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:88–93.PubMedCrossRefGoogle Scholar
  91. 91.
    Asano TK, McLeod RS. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2004:CD004079.Google Scholar
  92. 92.
    Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220–4.PubMedCrossRefGoogle Scholar
  93. 93.
    Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90.PubMedCrossRefGoogle Scholar
  95. 95.
    Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328–36.PubMedCrossRefGoogle Scholar
  96. 96.
    Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635–9.PubMedGoogle Scholar
  99. 99.
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.PubMedCrossRefGoogle Scholar
  100. 100.
    Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294:47–55.PubMedCrossRefGoogle Scholar
  101. 101.
    Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, ­Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med. 1998;128:713–20.PubMedGoogle Scholar
  102. 102.
    Dube C, Rostom A, Lewin G, et al. The use of aspirin for ­primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146:365–75.PubMedGoogle Scholar
  103. 103.
    Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13.PubMedCrossRefGoogle Scholar
  104. 104.
    Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674–82.PubMedCrossRefGoogle Scholar
  105. 105.
    Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology. 2003;125:404–12.PubMedCrossRefGoogle Scholar
  106. 106.
    Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.PubMedCrossRefGoogle Scholar
  107. 107.
    Grau MV, Sandler RS, McKeown-Eyssen G, et al. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;101:267–76.PubMedCrossRefGoogle Scholar
  108. 108.
    Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649–58.PubMedCrossRefGoogle Scholar
  109. 109.
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888–99.PubMedCrossRefGoogle Scholar
  110. 110.
    Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–102.PubMedCrossRefGoogle Scholar
  111. 111.
    Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology. 2002;122:78–84.PubMedCrossRefGoogle Scholar
  112. 112.
    Hur C, Simon LS, Gazelle GS. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer. 2004;101:189–97.PubMedCrossRefGoogle Scholar
  113. 113.
    Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574–82.PubMedCrossRefGoogle Scholar
  114. 114.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and ­benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedCrossRefGoogle Scholar
  115. 115.
    Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991–1004.PubMedCrossRefGoogle Scholar
  116. 116.
    Newcomb PA, Zheng Y, Chia VM, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 2007;67:7534–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol. 2009;27:4542–7.PubMedCrossRefGoogle Scholar
  118. 118.
    Hoffmeister M, Raum E, Krtschil A, Chang-Claude J, Brenner H. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Ther. 2009;86:416–24.PubMedCrossRefGoogle Scholar
  119. 119.
    Purdue MP, Mink PJ, Hartge P, Huang WY, Buys S, Hayes RB. Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes Control. 2005;16:965–73.PubMedCrossRefGoogle Scholar
  120. 120.
    Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24:5680–6.PubMedCrossRefGoogle Scholar
  121. 121.
    Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ. 2003;326:322–6.PubMedCrossRefGoogle Scholar
  122. 122.
    Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry Jr CP, Edwards SM. Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord. 1998;22:178–84.PubMedCrossRefGoogle Scholar
  123. 123.
    Kune GA, Kune S, Watson LF. Body weight and physical activity as predictors of colorectal cancer risk. Nutr Cancer. 1990;13:9–17.PubMedCrossRefGoogle Scholar
  124. 124.
    Lin J, Zhang SM, Cook NR, Rexrode KM, Lee IM, Buring JE. Body mass index and risk of colorectal cancer in women (United States). Cancer Causes Control. 2004;15:581–9.PubMedCrossRefGoogle Scholar
  125. 125.
    Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007; 335:1134.PubMedCrossRefGoogle Scholar
  126. 126.
    Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol Biomarkers Prev. 2006;15:2391–7.PubMedCrossRefGoogle Scholar
  127. 127.
    Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556–65.PubMedGoogle Scholar
  128. 128.
    Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533–47.PubMedCrossRefGoogle Scholar
  129. 129.
    Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD. Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control. 2003;14:75–84.PubMedCrossRefGoogle Scholar
  130. 130.
    Wang Y, Jacobs EJ, Teras LR, et al. Lack of evidence for effect modification by estrogen of association between body mass index and colorectal cancer risk among postmenopausal women. Cancer Causes Control. 2007;18:793–9.PubMedCrossRefGoogle Scholar
  131. 131.
    Hoffmeister M, Raum E, Winter J, Chang-Claude J, Brenner H. Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. Br J Cancer. 2007;97:1486–92.PubMedCrossRefGoogle Scholar
  132. 132.
    Kim Y, Kim Y, Lee S. An association between colonic adenoma and abdominal obesity: a cross-sectional study. BMC Gastroenterol. 2009;9:4.PubMedCrossRefGoogle Scholar
  133. 133.
    Jacobs ET, Ahnen DJ, Ashbeck EL, et al. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol. 2009;169:657–66.PubMedCrossRefGoogle Scholar
  134. 134.
    Jacobs ET, Martinez ME, Alberts DS, et al. Association between body size and colorectal adenoma recurrence. Clin Gastroenterol Hepatol. 2007;5:982–90.PubMedCrossRefGoogle Scholar
  135. 135.
    Howard RA, Freedman DM, Park Y, Hollenbeck A, Schatzkin A, Leitzmann MF. Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2008;19:939–53.PubMedGoogle Scholar
  136. 136.
    Slattery ML. Physical activity and colorectal cancer. Sports Med. 2004;34:239–52.PubMedCrossRefGoogle Scholar
  137. 137.
    Samad AK, Taylor RS, Marshall T, Chapman MA. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis. 2005;7:204–13.PubMedCrossRefGoogle Scholar
  138. 138.
    Harriss DJ, Atkinson G, Batterham A, et al. Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. Colorectal Dis. 2009;11:689–701.PubMedCrossRefGoogle Scholar
  139. 139.
    Woodson K, Flood A, Green L, et al. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst. 2004;96:407–10.PubMedCrossRefGoogle Scholar
  140. 140.
    Haydon AM, Macinnis RJ, English DR, Morris H, Giles GG. Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut. 2006;55:689–94.PubMedCrossRefGoogle Scholar
  141. 141.
    Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132:3456S–64.PubMedGoogle Scholar
  142. 142.
    Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:725–31.PubMedGoogle Scholar
  143. 143.
    Paskett ED, Reeves KW, Rohan TE, et al. Association between cigarette smoking and colorectal cancer in the Women’s Health Initiative. J Natl Cancer Inst. 2007;99:1729–35.PubMedCrossRefGoogle Scholar
  144. 144.
    Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-­analysis. JAMA. 2008;300:2765–78.PubMedCrossRefGoogle Scholar
  145. 145.
    Chaiter Y, Gruber SB, Ben-Amotz A, et al. Smoking attenuates the negative association between carotenoids consumption and colorectal cancer risk. Cancer Causes Control. 2009;20(8):1327–38.PubMedCrossRefGoogle Scholar
  146. 146.
    Poynter JN, Haile RW, Siegmund KD, et al. Associations between smoking, alcohol consumption, and colorectal ­cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev. 2009;18:2745–50.PubMedCrossRefGoogle Scholar
  147. 147.
    Giovannucci E, Colditz GA, Stampfer MJ. A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology. 1993;105:130–41.PubMedGoogle Scholar
  148. 148.
    Lagergren J, Ye W, Ekbom A. Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? Gastroenterology. 2001;121:542–7.PubMedCrossRefGoogle Scholar
  149. 149.
    Schernhammer ES, Leitzmann MF, Michaud DS, et al. Cholecystectomy and the risk for developing colorectal cancer and distal colorectal adenomas. Br J Cancer. 2003;88:79–83.PubMedCrossRefGoogle Scholar
  150. 150.
    Shao T, Yang YX. Cholecystectomy and the risk of colorectal cancer. Am J Gastroenterol. 2005;100:1813–20.PubMedCrossRefGoogle Scholar
  151. 151.
    Goldacre MJ, Abisgold JD, Seagroatt V, Yeates D. Cancer after cholecystectomy: record-linkage cohort study. Br J Cancer. 2005;92:1307–9.PubMedCrossRefGoogle Scholar
  152. 152.
    Lieberman DA, Prindiville S, Weiss DG, Willett W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290:2959–67.PubMedCrossRefGoogle Scholar
  153. 153.
    Vinikoor LC, Robertson DJ, Baron JA, Silverman WB, Sandler RS. Cholecystectomy and the risk of recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2007;16:1523–5.PubMedCrossRefGoogle Scholar
  154. 154.
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.PubMedCrossRefGoogle Scholar
  155. 155.
    Jess T, Loftus Jr EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130:1039–46.PubMedCrossRefGoogle Scholar
  156. 156.
    Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2:1088–95.PubMedCrossRefGoogle Scholar
  157. 157.
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–33.PubMedCrossRefGoogle Scholar
  158. 158.
    Sharan R, Schoen RE. Cancer in inflammatory bowel disease. An evidence-based analysis and guide for physicians and patients. Gastroenterol Clin North Am. 2002;31:237–54.PubMedCrossRefGoogle Scholar
  159. 159.
    Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.PubMedCrossRefGoogle Scholar
  160. 160.
    Velayos FS, Loftus Jr EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941–9.PubMedCrossRefGoogle Scholar
  161. 161.
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.PubMedCrossRefGoogle Scholar
  162. 162.
    Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006:CD000279.Google Scholar
  163. 163.
    Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis. 2003;18:392–400.PubMedCrossRefGoogle Scholar
  164. 164.
    Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590–2.PubMedCrossRefGoogle Scholar
  165. 165.
    Mellemkjaer L, Johansen C, Gridley G, Linet MS, Kjaer SK, Olsen JH. Crohn’s disease and cancer risk (Denmark). Cancer Causes Control. 2000;11:145–50.PubMedCrossRefGoogle Scholar
  166. 166.
    Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006;42:216–27.PubMedCrossRefGoogle Scholar
  167. 167.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.PubMedCrossRefGoogle Scholar
  168. 168.
    Glanz K, Grove J, Le Marchand L, Gotay C. Underreporting of family history of colon cancer: correlates and implications. Cancer Epidemiol Biomarkers Prev. 1999;8:635–9.PubMedGoogle Scholar
  169. 169.
    Rubin DT, Gandhi RK, Hetzel JT, et al. Do colorectal cancer patients understand that their family is at risk? Dig Dis Sci. 2009;54:2473–83.PubMedCrossRefGoogle Scholar
  170. 170.
    Tamai O, Nozato E, Miyazato H, et al. Radiation-associated rectal cancer: report of four cases. Dig Surg. 1999;16:238–43.PubMedCrossRefGoogle Scholar
  171. 171.
    Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88:398–406.PubMedCrossRefGoogle Scholar
  172. 172.
    Park SS, Kim BK, Kim CJ, et al. Colorectal adenocarcinoma as a second malignant neoplasm following rhabdomyosarcoma of the urinary bladder: a case report. J Korean Med Sci. 2000;15:475–7.PubMedGoogle Scholar
  173. 173.
    Shirouzu K, Isomoto H, Morodomi T, Ogata Y, Araki Y, Kakegawa T. Clinicopathologic characteristics of large bowel cancer developing after radiotherapy for uterine cervical cancer. Dis Colon Rectum. 1994;37:1245–9.PubMedCrossRefGoogle Scholar
  174. 174.
    Woodhouse CR. Guidelines for monitoring of patients with ureterosigmoidostomy. Gut. 2002;51 Suppl 5:V15–6.PubMedCrossRefGoogle Scholar
  175. 175.
    Azimuddin K, Khubchandani IT, Stasik JJ, Rosen L, Riether RD. Neoplasia after ureterosigmoidostomy. Dis Colon Rectum. 1999;42:1632–8.PubMedCrossRefGoogle Scholar
  176. 176.
    Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13:395–400.PubMedCrossRefGoogle Scholar
  177. 177.
    Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab. 2001;86:2935–41.PubMedCrossRefGoogle Scholar
  178. 178.
    Terzolo M, Reimondo G, Gasperi M, et al. Colonoscopic screening and follow-up in patients with acromegaly: a ­multicenter study in Italy. J Clin Endocrinol Metab. 2005;90:84–90.PubMedCrossRefGoogle Scholar
  179. 179.
    Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, ­Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14:3484–9.PubMedCrossRefGoogle Scholar
  180. 180.
    Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet. 2002;360:273–7.PubMedCrossRefGoogle Scholar
  181. 181.
    Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85:3218–21.PubMedCrossRefGoogle Scholar
  182. 182.
    Bogazzi F, Cosci C, Sardella C, et al. Identification of ­acromegalic patients at risk of developing colonic adenomas. J Clin Endocrinol Metab. 2006;91:1351–6.PubMedCrossRefGoogle Scholar
  183. 183.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.PubMedCrossRefGoogle Scholar
  184. 184.
    Robbins DH, Itzkowitz SH. The molecular and genetic basis of colon cancer. Med Clin North Am. 2002;86:1467–95.PubMedCrossRefGoogle Scholar
  185. 185.
    Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras ­mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.PubMedCrossRefGoogle Scholar
  186. 186.
    Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med. 2002;137:603–12.PubMedGoogle Scholar
  187. 187.
    Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820–3.PubMedCrossRefGoogle Scholar
  188. 188.
    Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 1998;339:1277–84.PubMedCrossRefGoogle Scholar
  189. 189.
    Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol. 1998;16:3158–68.PubMedGoogle Scholar
  190. 190.
    Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype ­correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998;17:1061–8.PubMedCrossRefGoogle Scholar
  191. 191.
    Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol. 2004;25:258–63.PubMedCrossRefGoogle Scholar
  192. 192.
    Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. ­Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10:3069–75.PubMedCrossRefGoogle Scholar
  193. 193.
    Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. 2003;21:271–6.PubMedCrossRefGoogle Scholar
  194. 194.
    Fearon ER, Cho KR, Nigro JM, et al. Identification of a ­chromosome 18q gene that is altered in colorectal cancers. Science. 1990;247:49–56.PubMedCrossRefGoogle Scholar
  195. 195.
    Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 1996;335:1727–32.PubMedCrossRefGoogle Scholar
  196. 196.
    Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91:916–32.PubMedCrossRefGoogle Scholar
  197. 197.
    Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.PubMedCrossRefGoogle Scholar
  198. 198.
    Ward R, Meagher A, Tomlinson I, et al. Microsatellite ­instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001;48:821–9.PubMedCrossRefGoogle Scholar
  199. 199.
    Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in ­colorectal carcinoma. Cancer. 2001;91:2417–22.PubMedCrossRefGoogle Scholar
  200. 200.
    Jass JR, Do KA, Simms LA, et al. Morphology of ­sporadic ­colorectal cancer with DNA replication errors. Gut. 1998;42:673–9.PubMedCrossRefGoogle Scholar
  201. 201.
    Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77.PubMedCrossRefGoogle Scholar
  202. 202.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedCrossRefGoogle Scholar
  203. 203.
    Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001;10:735–40.PubMedCrossRefGoogle Scholar
  204. 204.
    Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36:801–18.PubMedGoogle Scholar
  205. 205.
    Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998;58:3455–60.PubMedGoogle Scholar
  206. 206.
    Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C  →  T:A mutations in colorectal tumors. Nat Genet. 2002;30:227–32.PubMedCrossRefGoogle Scholar
  207. 207.
    Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003;348:791–9.PubMedCrossRefGoogle Scholar
  208. 208.
    Jenkins MA, Croitoru ME, Monga N, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev. 2006;15:312–4.PubMedCrossRefGoogle Scholar
  209. 209.
    Peterlongo P, Mitra N, Sanchez de Abajo A, et al. Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis. 2006;27:2243–9.PubMedCrossRefGoogle Scholar
  210. 210.
    Croitoru ME, Cleary SP, Di Nicola N, et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst. 2004; 96:1631–4.PubMedCrossRefGoogle Scholar
  211. 211.
    Balaguer F, Castellvi-Bel S, Castells A, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol. 2007;5:379–87.PubMedCrossRefGoogle Scholar
  212. 212.
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.PubMedCrossRefGoogle Scholar
  213. 213.
    Bird RP, Good CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett. 2000;112–113:395–402.PubMedCrossRefGoogle Scholar
  214. 214.
    Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–7.PubMedCrossRefGoogle Scholar
  215. 215.
    Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. 2004;23:11–27.PubMedCrossRefGoogle Scholar
  216. 216.
    Rosenberg DW, Yang S, Pleau DC, et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-­serrated hyperplastic aberrant crypt foci in humans. Cancer Res. 2007;67:3551–4.PubMedCrossRefGoogle Scholar
  217. 217.
    Messick CA, Church J, Casey G, Kalady MF. Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum. 2009;52:1535–41.PubMedCrossRefGoogle Scholar
  218. 218.
    Higuchi T, Jass JR. My approach to serrated polyps of the colorectum. J Clin Pathol. 2004;57:682–6.PubMedCrossRefGoogle Scholar
  219. 219.
    Yang S, Farraye FA, Mack C, Posnik O, O’Brien MJ. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol. 2004;28:1452–9.PubMedCrossRefGoogle Scholar
  220. 220.
    Young J, Jenkins M, Parry S, et al. Serrated pathway colorectal cancer in the population: genetic consideration. Gut. 2007;56:1453–9.PubMedCrossRefGoogle Scholar
  221. 221.
    Jass JR. Pathogenesis of colorectal cancer. Surg Clin North Am. 2002;82:891–904.PubMedCrossRefGoogle Scholar
  222. 222.
    Jass JR. Serrated route to colorectal cancer: back street or super highway? J Pathol. 2001;193:283–5.PubMedCrossRefGoogle Scholar
  223. 223.
    Kakar S, Burgart LJ, Thibodeau SN, et al. Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer. 2003;97:1421–7.PubMedCrossRefGoogle Scholar
  224. 224.
    Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000;97:710–5.PubMedCrossRefGoogle Scholar
  225. 225.
    Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.PubMedCrossRefGoogle Scholar
  226. 226.
    Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137–44.PubMedCrossRefGoogle Scholar
  227. 227.
    Fukuyama R, Niculaita R, Ng KP, et al. Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene. 2008;27:6044–55.PubMedCrossRefGoogle Scholar
  228. 228.
    Kohonen-Corish MR, Sigglekow ND, Susanto J, et al. ­Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene. 2007;26:4435–41.PubMedCrossRefGoogle Scholar
  229. 229.
    Burt J, Jass J. Hyperplastic polyposis. In: Hamilton S, ­Aaltonen L, editors. World Health Organisation classification of tumors Pathology and Genetics Tumors of the digestive system. Lyon: IARC Press; 2000.Google Scholar
  230. 230.
    Beach R, Chan AO, Wu TT, et al. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol. 2005;166:1069–75.PubMedCrossRefGoogle Scholar
  231. 231.
    Young J, Barker MA, Simms LA, et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol. 2005;3:254–63.PubMedCrossRefGoogle Scholar
  232. 232.
    Yeung TM, Mortensen NJ. Colorectal cancer stem cells. Dis Colon Rectum. 2009;52:1788–96.PubMedCrossRefGoogle Scholar
  233. 233.
    Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene. 2007;26:1357–60.PubMedCrossRefGoogle Scholar
  234. 234.
    Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67:8980–4.PubMedCrossRefGoogle Scholar
  235. 235.
    O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.PubMedCrossRefGoogle Scholar
  236. 236.
    Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.PubMedCrossRefGoogle Scholar
  237. 237.
    Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449:1003–7.PubMedCrossRefGoogle Scholar
  238. 238.
    Sangiorgi E, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. Nat Genet. 2008;40:915–20.PubMedCrossRefGoogle Scholar
  239. 239.
    Subramaniam V, Vincent IR, Gilakjan M, Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol. 2007;83:332–40.PubMedCrossRefGoogle Scholar
  240. 240.
    Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457:608–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Harvey G. Moore
    • 1
  • Nancy N. Baxter
    • 2
  • Jose G. Guillem
    • 3
  1. 1.Department of SurgeryNew York University School of MedicineNew YorkUSA
  2. 2.Department of Surgery, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  3. 3.Department of Colorectal SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations